View Older Stories View More Recent Stories

May 26, 2020 04:30PM Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
May 13, 2020 05:23PM Allogene Therapeutics (ALLO) ASCO Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
May 13, 2020 05:00PM American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
May 13, 2020 05:00PM American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
May 6, 2020 07:30AM Allogene Therapeutics Reports First Quarter 2020 Financial Results
May 6, 2020 07:30AM Allogene Therapeutics Reports First Quarter 2020 Financial Results
Apr 29, 2020 11:43AM Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the Ameri
Apr 29, 2020 11:42AM Allogene Therapeutics, in Collaboration with Servier, to Present Initial Results from its Phase 1 ALPHA Study of ALLO-501 AlloCAR T™ Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma at the Ameri
Apr 28, 2020 04:39PM Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR™ Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting
Apr 28, 2020 04:39PM Allogene Therapeutics to Present Preclinical Findings Supporting TurboCAR™ Technology at the American Society of Gene & Cell Therapy (ASGCT) Virtual 2020 Annual Meeting
Apr 27, 2020 08:30AM Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020
Apr 27, 2020 08:30AM Allogene Therapeutics to Report First Quarter 2020 Financial Results on May 6, 2020
Apr 1, 2020 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Apr 1, 2020 08:30AM Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences
Mar 24, 2020 07:00AM MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies
Feb 27, 2020 04:30AM Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 27, 2020 04:30AM Allogene Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 19, 2020 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Feb 19, 2020 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Feb 6, 2020 08:30AM Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
Feb 6, 2020 08:30AM Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
Feb 6, 2020 08:30AM Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
Jan 13, 2020 06:03AM Allogene Therapeutics (ALLO), SpringWorks (SWTX) Therapeutics Report Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Jan 13, 2020 06:00AM Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Jan 13, 2020 06:00AM Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Jan 2, 2020 08:30AM Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 2, 2020 08:30AM Allogene Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Nov 11, 2019 08:30AM Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
Nov 11, 2019 08:30AM Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
Nov 6, 2019 09:02AM Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
Nov 6, 2019 09:02AM Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
Nov 5, 2019 07:30AM Allogene Therapeutics Reports Third Quarter 2019 Financial Results
Nov 5, 2019 07:30AM Allogene Therapeutics Reports Third Quarter 2019 Financial Results
Nov 5, 2019 06:30AM Allogene Therapeutics (ALLO) Reports Collaboration with Notch Therapeutics to Research & Develop iPSC-Derived Allogeneic Therapies for Hematologic Cancer Indications
Nov 5, 2019 06:28AM Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
Nov 5, 2019 06:28AM Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
Oct 29, 2019 08:30AM Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019
Oct 29, 2019 08:30AM Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019
Sep 19, 2019 08:04AM Allogene Therapeutics (ALLO) Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Sep 19, 2019 08:00AM Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Sep 19, 2019 08:00AM Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Sep 3, 2019 08:30AM Allogene Therapeutics Announces September 2019 Investor Conference Schedule
Sep 3, 2019 08:30AM Allogene Therapeutics Announces September 2019 Investor Conference Schedule
Aug 7, 2019 07:30AM Allogene Therapeutics Reports Second Quarter 2019 Financial Results
Aug 7, 2019 07:30AM Allogene Therapeutics Reports Second Quarter 2019 Financial Results
Aug 5, 2019 06:28AM Allogene Therapeutics (ALLO) Appoints Rafael G. Amado, M.D. as EVP of R&D and CMO
Aug 5, 2019 06:00AM Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
Aug 5, 2019 06:00AM Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
Aug 1, 2019 06:00AM Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation
Jul 29, 2019 08:30AM Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
View More Recent Stories View Older Stories